Study results inspire Bird Rock Bio hopes to slash cost of RA treatment
California-based biopharmaceutical company Bird Rock Bio has announced study results which could bring an affordable treatment for rheumatoid arthritis (RA) closer for patients around the world.
Bird Rock Bio, formerly known as RuiYi, revealed positive results from two clinical studies on gerilimzumab, a novel anti-IL-6 cytokine antibody for the treatment of inflammatory diseases, including RA.
In both studies, gerilimzumab demonstrated safety as well as pharmacokinetic support for very low dosing of the drug of less than 50mg per patient, per year. Just one subcutaneous injection every eight weeks is required.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze